Integrating New Advances into Community Oncology Practice — In Partnership with Florida Cancer Specialists & Research Institute — Multiple Myeloma

Faculty

TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

LEARNING OBJECTIVES

Breast Cancer

• Evaluate recently presented clinical research findings to determine their effect on the current management of localized or metastatic breast cancer.
• Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for hormone receptor (HR)-positive localized or metastatic breast cancer in order to appropriately counsel patients regarding the optimal clinical use of these agents.
• Recognize the biological rationale for the development of agents targeting the PI3K/AKT/mTOR pathway, and recognize available data with FDA-approved treatments for patients with HR-positive metastatic breast cancer (mBC) with and without PIK3CA/AKT1/PTEN alterations.
• Understand the mechanism of action of, published research findings with and current and future clinical role of oral selective estrogen receptor degraders (SERDs) alone and in combination with other agents and of PROTAC (PROteolysis TArgeting Chimera) ER degraders for patients with HR-positive mBC harboring ESR1 mutations.
• Analyze the scientific justification for, available data with and potential clinical role of oral SERDs as adjuvant treatment for localized HR-positive, HER2-negative breast cancer.
• Evaluate published research findings to effectively inform the selection and sequencing of available therapeutic agents and regimens for HER2-positive localized and metastatic breast cancer.
• Review published research data supporting the use of chemotherapy or antibody-drug conjugate (ADC) therapy in combination with anti-PD-1/PD-L1 antibodies for localized or metastatic triple-negative breast cancer, and use this information to make appropriate treatment recommendations.
• Interrogate published Phase III research findings documenting the efficacy of TROP2-directed ADC monotherapy for mBC to determine the current clinical applicability of this approach.
• Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for localized and metastatic breast cancer.

Prostate Cancer

• Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for individual patients considering the potential benefits and risks of new and established forms of hormonal therapy.
• Evaluate the biological rationale for and available data with perioperative androgen deprivation therapy in combination with an androgen receptor (AR) pathway inhibitor for high-risk localized or locally advanced prostate cancer, and review the potential clinical role of this novel strategy.
• Appraise published research findings on optimal management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into current clinical management algorithms.
• Assess the available research database supporting the use of PARP inhibitors in combination with AR pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
• Evaluate available data with novel AKT inhibitors in combination with hormonal therapy for mHSPC with PTEN deficiency, and identify patients who may be appropriate for this form of treatment.
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for R/R MM.
• Develop an understanding of the current clinical research database with various chimeric antigen receptor T-cell therapy platforms in the management of R/R MM in order to optimally integrate this novel therapeutic strategy into current treatment algorithms.
• Assess available research data with B-cell maturation antigen (BCMA) and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into current clinical algorithms.
• Recall recently presented clinical research findings establishing the definitive efficacy of BCMA-directed ADC therapy for R/R MM, and identify patients appropriate for treatment with these agents.
• Analyze the mechanism of action of, published efficacy and safety findings with and the current and future clinical role of cereblon E3 ligase modulators in the management of R/R MM.
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed in the care of patients with R/R MM.
• Recall available data with novel agents and strategies currently under investigation for R/R MM, and discuss clinical trial participation with eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 4.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Agarwal has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Antonarakis — Advisory Committees: Abeona Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Curium, Merck, Pfizer Inc, Sanofi, Tango Therapeutics, Tempus, Vir Biotechnology Inc; Consulting Agreements: Acerand Therapeutics, Blue Earth Diagnostics, Boundless Bio, Clarivate, Clearview Healthcare Partners, Curium, DAVA Oncology, EcoR1 Capital LLC, Global Life Sciences Alliance, Health Monitor Network, Johnson & Johnson, Lilly, Lumanity, Propella Therapeutics Inc, Slingshot Insights, Third Bridge, Z-Alpha; Contracted Research: Actinium Pharmaceuticals Inc, MacroGenics Inc, Merck, MorphoSys, Novartis, Orion Corporation, pharmaand GmbH, Seagen; Patents: Qiagen; Nonrelevant Financial Relationships: Binaytara Foundation, Conexiant, eCancer, Fred Hutch Cancer Center, MJH Life Sciences, Targeted Oncology, The Medical Educator Consortium. Dr Geyer — Contracted Research: Abbott, Artera, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group. Dr Lonial — Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Boards of Directors: TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: TG Therapeutics Inc. Dr Lustberg — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Sandoz Inc, a Novartis Division; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP. Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics. Dr Richardson — Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Karyopharm Therapeutics, Oncopeptides. Dr Wander — Advisory Committees: AstraZeneca Pharmaceuticals LP, Celcuity, Genentech, a member of the Roche Group, Lilly, Menarini Group, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc; Consulting Agreements: 2nd.MD, Arvinas, Biovica International AB, Boundless Bio, Daiichi Sankyo Inc, Delcath Systems Inc, Foundation Medicine, Gilead Sciences Inc, Halda Therapeutics, Novartis, Pfizer Inc, Precede Biosciences, TerSera Therapeutics LLC, Veracyte Inc; Contracted Research: Arvinas, Boundless Bio, Genentech, a member of the Roche Group, Halda Therapeutics, Lilly, Menarini Group, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc.

MODERATOR — Dr Love  is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Johnson & Johnson, Kite, A Gilead Company, Novartis, Puma Biotechnology Inc, Rigel Pharmaceuticals Inc, and Stemline Therapeutics Inc.

Release date: November 9, 2026
Expiration date: November 9, 2027

Dr Lonial

Bal S et al. Arlocabtagene autoleucel: A GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma. Blood 2026;148(10):1240-50. Abstract

Bal S et al. Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated relapsed/refractory (RR) multiple myeloma (MM). ASH 2024;Abstract 922.

Cohen AD et al. Long-term (≥5-year) remission and survival with ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (RRMM) with 1–3 prior lines of therapy: CARTITUDE-2 cohort A. IMS 2026;Abstract PA-288.

Costa LJ et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med 2026;394(8):739-52. Abstract

Einsele H et al. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): An updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2026;27(2):254-68. Abstract

Lebel E et al. QUINTESSENTIAL-2: A phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide. ASCO 2026;Abstract TPS7577.

Martin T et al. iMMagine-3: A phase 3, randomized study to compare the efficacy and safety of anitocabtagene autoleucel (anito-cel) with standard of care in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2024;Abstract PB2724.

Mateos MV et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (pts) with relapsed refractory multiple myeloma (RRMM): Results of MajesTEC-3. ASH 2025;Abstract LBA-6.

Mina R et al. MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM). ASCO 2026;Abstract 7507.

Mina R et al. Talquetamab-daratumumab in relapsed or refractory myeloma. N Engl J Med 2026;395(7):671-83. Abstract

Patel K et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine-1. ASH 2025;Abstract 256.

Touzeau C et al. Teclistamab in multiple myeloma with one to three previous lines of therapy. N Engl J Med 2026;395(5):440-53. Abstract

Voorhees PM et al. Phase 3, randomized study of talquetamab (Tal) plus daratumumab (D) ± pomalidomide (P) vs D plus P and dexamethasone (DPd) in relapsed/refractory multiple myeloma (RRMM): MonumenTAL-3. IMS 2026;Abstract PA-350.

Voorhees PM et al. Phase 3, randomized study of talquetamab (Tal) plus daratumumab (Dara) ± pomalidomide (Pom) vs Dara plus Pom and dexamethasone (DPd) in relapsed/refractory multiple myeloma (RRMM): MonumenTAL-3. EHA 2026;Abstract S100.

Dr Richardson

Determination 2 – Isatuximab, iberdomide, bortezomib and dexamethasone induction, followed by risk- and response-adapted consolidation and maintenance therapy, in transplant-eligible patients with newly diagnosed multiple myeloma. NCT07624513

Dimopoulos MA et al. Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial. IMS 2026;Abstract PA-305.

Dimopoulos MA et al. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): A phase 3, open-label, randomised controlled trial. Lancet 2026;408(10551):219-33. Abstract

Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Updated 4-year results of the phase 3 DREAMM-7 trial. IMS 2026;Abstract PA-049.

Lonial S et al. Iberdomide, daratumumab, dexamethasone (IberDd) vs daratumumab, bortezomib, dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM): Results from EXCALIBER-RRMM phase 3 study. IMS 2026;Abstract LBA-12.

Lonial S et al. Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): An open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2026;27(11):1367-81. Abstract

Mateos MV et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv 2025;9(22):5708-19. Abstract

Richardson PG et al. Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial. ASCO 2026;Abstract LBA7506.

Trudel S et al. Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8. IMS 2026;Abstract OA-38.

Trudel S et al. Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study. ASH 2025;Abstract 2264.

Usmani SZ et al. DREAMM-9 patient-reported vision-related function with extended belantamab mafodotin dosing intervals with bortezomib, lenalidomide, dexamethasone (BVRd) in transplant ineligible multiple myeloma. IMS 2026;Abstract OA-20.